• Explore /
  • Poster
  • / Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.

Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.

Abstract Poster

Authors

null

Emmanuel S. Antonarakis

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Emmanuel S. Antonarakis , Hao Wang , Benjamin A. Teply , Jamie Willms , Rana Sullivan , Serina King , Catherine Handy Marshall , Tamara L. Lotan , William Kevin Kelly

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT03047135

Citation

J Clin Oncol 37, 2019 (suppl; abstr 5045)

DOI

10.1200/JCO.2019.37.15_suppl.5045

Abstract #

5045

Poster Bd #

157

Abstract Disclosures

Similar Posters

First Author: Benjamin A. Teply

First Author: Catherine Handy Marshall

First Author: Rana R. McKay

First Author: Kamal Kant Kant Sahu